Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

OCGN
Ocugen, Inc. Common Stock
stock NASDAQ

At Close
Jun 17, 2025 3:59:47 PM EDT
1.09USD-6.466%(-0.07)5,201,777
0.00Bid   0.00Ask   0.00Spread
Pre-market
Jun 17, 2025 9:26:30 AM EDT
1.17USD+0.862%(+0.01)145,356
After-hours
Jun 17, 2025 4:55:30 PM EDT
1.12USD+3.226%(+0.03)42,323
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 28, 2022
07:18AM EST  Bharat Biotech Tweets Intranasal COVID-19 vaccine, BBV154, has received DCGI approval for Phase-3 clinical trials; News Was First Announced Earlier Today   Benzinga
07:18AM EST  Bharat Biotech's Tweets Intranasal COVID-19 vaccine, BBV154, has received DCGI approval for Phase-3 clinical trials; News Was First Announced Earlier Today   Benzinga
Jan 27, 2022
09:28AM EST  Ocugen Signs Letter Of Intent To Acquire Vaccine Manufacturing, R&D Hub In Ontario, Canada   Benzinga
09:25AM EST  Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine   GlobeNewswire Inc
04:49AM EST  India's DCGI Granted Conditional Market Approval for Covishield and Covaxin   Benzinga
Jan 24, 2022
09:41AM EST  Ocugen Sponsored Study 'The Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa' Posted to ClinicalTrials Website; Study Not Yet Recruiting   Benzinga
07:12AM EST  Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the appointment of Nirdosh Jagota, Ph.D., as Senior Vice President (SVP), Regulatory Affairs, compliance and safety.   GlobeNewswire Inc
Jan 21, 2022
06:12PM EST  Ocugen, Inc.Announces Inducement Grants   GlobeNewswire Inc
Jan 19, 2022
11:36AM EST  India's CDSCO Has Recommended For Upgrade Of Covishield, Covaxin Status From Restricted Use In Emergency Situations   Benzinga
Jan 14, 2022
09:53AM EST  Bharat Biotech's Subject Expert Committee Sought More Data From Co, Serum Institute Before Granting Complete Licensure For Covaxin, COVISHIELD. BZ NOTE: Ocugen Is A Partner With Co On Covaxin   Benzinga
Jan 13, 2022
12:37PM EST  'Bharat Biotech writes to DCGI seeking full marketing approval for Covaxin' -TimesNowNews Report. BZ NOTE: Ocugen Is A Partner With Bharat Bioitech On Covaxin   Benzinga
Jan 12, 2022
08:30AM EST  The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award   Benzinga
06:44AM EST  Ocugen And Bharat Biotech Announce Results From Study Demonstrating A Booster Dose Of COVAXIN 'generated robust neutralizing antibody responses' Against Omicron And Delta   Benzinga
06:43AM EST  COVAXIN (BBV152) Booster Shown to Neutralize   GlobeNewswire Inc
Jan 10, 2022
07:47AM EST  Why Ocugen Is Rising In Pre-market?   RTTNews
Jan 8, 2022
07:30PM EST  Ocugen Announced Partner Bharat Biotech's COVAXIN Booster Dose Study Demonstrated Robust Immune Responses and Long-Term Safety; Participants Receiving Booster Dose Six months after Second Dose Saw >10-Fold Increase Across Alpha, Beta, Delta and Delta Plus Variants in Neutralizing Titers vs Baseline   Benzinga
06:27PM EST  COVAXIN (BBV152) Booster Dose Study Demonstrates   GlobeNewswire Inc
Jan 6, 2022
06:03PM EST  Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it will be participating in H.C. Wainwrights Bioconnect Conference taking place next week on January 10-13, 2022.   GlobeNewswire Inc
Jan 1, 2022
12:31PM EST  Top 25 WallStreetBets Mentions for 2021   Benzinga
Dec 30, 2021
01:10PM EST  Biopharmaceutical company Ocugen, Inc. (OCGN), Thursday announced that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, Covaxin, in children, aged 2 - 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv.   RTTNews
10:07AM EST  Bharat Biotech Reports Positive Data From COVAXIN, COVID-19 Candidate Vaccine, In Children 2- 18 Yrs   RTTNews
10:00AM EST  Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity And Safety Data From COVAXIN (BBV152), COVID-19 Candidate Vaccine, In Children 2 18 YEARS   Benzinga
10:00AM EST  Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity   GlobeNewswire Inc
08:56AM EST  Watching Ocugen Shares; Times Of India Reports 'Covaxin showed better antibody response in 2-18 year olds than adults: Bharat Biotech'   Benzinga
Dec 27, 2021
06:06AM EST  A Peek Into The Markets: US Stock Futures Edge Higher Following Thursday's Rally   Benzinga
Dec 25, 2021
03:09PM EST  Drugs Controller General Of India Has Given Bharat Biotech Covaxin Emergency Use Approval For 12-18 Year Olds   Benzinga
Dec 20, 2021
04:32PM EST  Ocugen, Inc.Announces Inducement Grants   GlobeNewswire Inc
07:25AM EST  The following are some of the stocks making big moves in Monday's pre-market trading (as of 07.10 A.M. ET).   RTTNews
Dec 15, 2021
10:34AM EST  Ocugen Partnered COVID-19 Vaccine Candidate Generates Immune Memory At Least 6 Months After Vaccination   Benzinga
06:50AM EST  Ocugen Highlights Data Analyzing Immune Response From Two Doses Of COVAXIN; Says Study Found COVAXIN 'generated a robust immune memory against spike and nucleoprotein that was comparable to that following natural COVID-19 Infection...'   Benzinga
06:46AM EST  New Data Suggest COVAXIN (BBV152) Vaccine   GlobeNewswire Inc
Dec 9, 2021
09:46PM EST  Ocugen, Inc. Announces U.S. FDA Acceptance Of Investigational New Drug Application To Initiate A Phase 1/2 Clinical Trial For Gene Therapy Candidate OCU400 To Treat Inherited Retinal Degeneration   Benzinga
07:38AM EST  Ocugen: FDA Accepts IND Application To Begin Phase 1/2 Trial For OCU400 To Treat Inherited Retinal Degeneration   RTTNews
07:28AM EST  -- Gene therapy candidate has potential to address a large number of retinitis pigmentosa and Leber congenital amaurosis gene mutations with a single product -- Trial to start in Q1 2022 will enroll patients with mutations in NR2E3 or RHO genes   GlobeNewswire Inc
Dec 2, 2021
01:18PM EST  GlaxoSmithKline Says Will Continue To Supply Adjuvant (AS01E) To Ocugen Partner Bharat Bio; Product Transfer Also Under Way With Bharat   Benzinga
Nov 30, 2021
04:39PM EST  Ocugen Partner, India's Bharat Biotech, Says It Is Studying if Covaxin Shot Will Work on Omicron Coronavirus Variant   Benzinga
Nov 29, 2021
06:39AM EST  Ocugen Partner Bharat Biotech Announced Monday it has Resumed Exports of COVID-19 Vaccine Covaxin   Benzinga
Nov 26, 2021
07:08AM EST  The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.00 A.M. ET).   RTTNews
07:02AM EST  Ocugen Announces FDA Has Issued Clinical Hold On Investigational New Drug Application To Evaluate COVAXIN   Benzinga
07:01AM EST  Ocugen, Inc. Provides an Update on its Investigational New Drug   GlobeNewswire Inc
Nov 24, 2021
01:51PM EST  Ocugen-Partnered Bharat Biotech's COVID-19 Shot Shows 50% Effectiveness In Small Study In India   Benzinga
Nov 23, 2021
02:20PM EST  Watching Shares Of Ocugen; Traders Circulate The Lancet Report Titled 'Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study' BZ NOTE: Ocugen Is A Partner With Bharat Biotech On SARS-CoV-2 Vaccine   Benzinga
02:19PM EST  Watching Shares Of Ocugen; Traders Circulate The Lancet Report Titled 'Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study'   Benzinga
Nov 18, 2021
04:03PM EST  Ocugen Inc.Announces Inducement Grants Under Nasdaq   GlobeNewswire Inc
Nov 11, 2021
02:27PM EST  Ocugen Issues Statement Regarding Publication Of COVAXIN (BBV152) Phase 3 Study Results In The Lancet   Benzinga
Nov 9, 2021
01:44PM EST  Ocugen Shares Quiet Following Headline Gates Ventures, Coalition for Epidemic Preparedness Innovations Will Fund Indian Vaccine Makers; BZ NOTE: Ocugen Is COVID-19 Vaccine Partner For India's Bharat Biotech   Benzinga
11:42AM EST  The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data   Benzinga
11:34AM EST  Ocugen Q3 EPS $(0.05) Misses $(0.04) Estimate   Benzinga
11:25AM EST  Earnings Scheduled For November 9, 2021   Benzinga
07:30AM EST  Ocugen Provides Business Update and Third Quarter 2021 Financial   GlobeNewswire Inc
Nov 8, 2021
11:18AM EST  Ocugen Option Alert: Jan 21 $12.5 Calls at the Ask: 199 @ $1.96 vs 6049 OI; Earnings 11/9 Before Open Ref=$9.405   Benzinga
09:25AM EST  Ocugen, Inc. Announces Submission Of Investigational New Drug Application With US FDA To Initiate Phase 1/2 Clinical Trial Evaluating Gene Therapy Candidate OCU400 (AAV-NR2E3) To Treat Inherited Retinal Degeneration   Benzinga
09:24AM EST  Ocugen, Inc. Announces Submission of Investigational New Drug   GlobeNewswire Inc
Nov 5, 2021
01:40PM EDT  Ocugen Seeks FDA Emergency Use Nod For Covaxin COVID-19 Vaccine In Kids   Benzinga
10:51AM EDT  Ocugen Option Alert: Nov 19 $10 Calls Sweep (14) above Ask!: 154 @ $1.828 vs 9844 OI; Earnings 11/9 Before Open Ref=$10.35   Benzinga
09:43AM EDT  The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill   Benzinga
09:38AM EDT  Ocugen Reports Submission Of Emergency Use Authorization Request To FDA For COVID-19 Vaccine COVAXIN For Children Aged 2-18 Years   Benzinga
06:38AM EDT  Ocugen, Inc. Announces Submission of Emergency Use Authorization   GlobeNewswire Inc
Nov 4, 2021
12:10PM EDT  WHO Chief Scientist Swaminathan Says Bharat Biotech's Covaxin Showed About 70% Efficacy Against Delta Variant Of COVID   Benzinga
Nov 3, 2021
11:31AM EDT  Shares of biotechnology company Ocugen, Inc. (OCGN) shares are down 11 percent on Wednesday's trading thus breaking the stock's upward trend since the past few days. The stock has been on an upward trajectory since submitting NDA for Phase 3 clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26.   RTTNews
09:21AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Nov. 3, 2021: OCGN, ADP, BBBY, KOSS, PHUN   Benzinga
09:19AM EDT  'WHO has granted emergency use listing (EUL) to #COVAXIN (developed by Bharat Biotech), adding to a growing portfolio of vaccines validated by WHO for the prevention of #COVID19' -Tweet From World Health Organization   Benzinga
09:14AM EDT  Ocugen Partner Bharat Biotech Tweeted: The CDSCO (Central Drugs Standard Control Organisation) has Approved the Extension of Shelf Life of Covaxin Up to 12 Months from Date of Manufacture   Benzinga
Nov 2, 2021
06:29PM EDT  Top 10 WallStreetBets Trending Stocks For Afternoon Of Tuesday, Nov. 2, 2021   Benzinga
02:48PM EDT  Ocugen shares were trading higher following a report its partner Bharat Biotech's Covaxin is recognized by Guyana for travellers.   Benzinga
12:58PM EDT  Ocugen Option Alert: Apr 14 $20 Calls at the Ask: 100 @ $4.0 vs 46 OI; Earnings 11/16 Before Open [est] Ref=$13.71   Benzinga
12:21PM EDT  Check Out What Whales Are Doing With OCGN   Benzinga
10:41AM EDT  Ocugen Partner Bharat Biotech's Covaxin Recognized by Guyana for Travellers   Benzinga
Nov 1, 2021
02:00PM EDT  What's Going On With Ocugen's Stock?   Benzinga
12:56PM EDT  Ocugen Option Alert: Nov 12 $20 Calls at the Ask: 150 @ $1.97 vs 335 OI; Earnings 11/12 Before Open [est] Ref=$13.985   Benzinga
10:36AM EDT  Ocugen, Inc. (OCGN) shares are rising more than 9 percent on Monday morning continuing an uptrend since it submitted NDA for Phase 3 Clinical trial of its COVID-19 vaccine candidate COVAXIN (BBV152) on October 26. There were no corporate announcements on the day to impact the stock movement.   RTTNews
10:09AM EDT  Ocugen Option Alert: Fri $12.5 Calls at the Ask: 192 @ $2.31 vs 3907 OI; Earnings 11/12 Before Open [est] Ref=$12.64   Benzinga
Oct 29, 2021
02:49PM EDT  Watching Ocugen Shares; Traders Circulate Thursday Report From Bestinau.net 'Covaxin can get WHO approval as soon as discussions progress, Shringla says' Highlighting Comments From India Foreign Minister Harsh Vardhan Shringla   Benzinga
02:48PM EDT  Watching Ocugen Shares; Traders Circulate Thursday Report From Bestinau.net 'Covaxin can get WHO approval as soon as discussions progress, Shringla says Highlighting Comments From India Foreign Minister Harsh Vardhan Shringla   Benzinga
02:47PM EDT  Watching Ocugen Shares; Traders Circulate Thursday Report From Bestinau.net 'Covaxin can get WHO approval as soon as discussions progress, Shringla says Highlighting Comments From India Foreign Minister Harsh Vardhan   Benzinga
01:57PM EDT  Ocugen Option Alert: Nov 12 $11 Calls Sweep (5) near the Ask: 120 @ $2.675 vs 966 OI; Earnings 11/9 Before Open [est] Ref=$11.6518   Benzinga
07:50AM EDT  'Secretary, Department of Biotechnology,Govt of India, @RenuSwarup says Bharat Biotech's Bengaluru facility has started operations, very quickly in a couple of weeks you will see the augmentation of their capacities' -CNBC-TV18 Tweet   Benzinga
Oct 27, 2021
12:29PM EDT  'Oman approves Covaxin Covid-19 vaccines for travel without quarantine' -The Times Of India Report   Benzinga
06:46AM EDT  Ocugen Announced Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN   Benzinga
06:36AM EDT  Ocugen, Inc. Announces Submission of Investigational New Drug Application With FDA to Initiate a Phase 3 Clinical Trial Evaluating Covid-19 Vaccine Candidate Covaxin   Benzinga
06:35AM EDT  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that it has submitted an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) to evaluate the COVID-19 vaccine candidate, BBV152, known as COVAXIN outside the United States.   GlobeNewswire Inc
Oct 26, 2021
02:00PM EDT  UPDATE: WHO Tells Benzinga 'The [Technical Advisory Group] expects to receive these clarifications from the manufacturer by the end of this week, and aims to reconvene for the final risk-benefit assessment on Wednesday, 3 November.'   Benzinga
01:59PM EDT  WHO, On Covaxin Approval, Tells Benzinga The Technical Advisory Group 'met today (26 October 2021) and decided that additional clarifications from the manufacturer are needed to conduct a final EUL risk-benefit assessment for global use of the vaccine.'   Benzinga
11:04AM EDT  Watching Shares Of Ocugen; LiveMint Reports 'Covaxin: Bharat Biotech's Covid vaccine may get approval 'within next 24 hrs', says WHO official' BZ NOTE: Ocugen Is A Partner On Covaxin   Benzinga
10:33AM EDT  Ocugen Option Alert: Fri $8 Calls at the Ask: 50 @ $5.15 vs 4500 OI; Earnings 11/9 Before Open [est] Ref=$13.0799   Benzinga
06:03AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.45 A.M. EDT).   RTTNews
Oct 19, 2021
08:48AM EDT  Ocugen To Present Pre-clinical Data For OCU410 At 2nd Annual Dry AMD Therapeutic Development Conference   RTTNews
08:38AM EDT  Ocugen Inc. To Present Pre-Clinical Data For OCU410 At 2nd Annual Dry AMD Therapeutic Development Conference Oct. 20   Benzinga
08:34AM EDT  Ocugen Inc. to present pre-clinical data for OCU410 at 2nd Annual   GlobeNewswire Inc
Oct 18, 2021
12:56PM EDT  Ocugen Option Alert: Oct 29 $9 Calls Sweep (28) near the midpoint: 505 @ $1.012 vs 1865 OI; Earnings 11/5 Before Open [est] Ref=$8.589   Benzinga
12:56PM EDT  Ocugen Option Alert: Jan 21 $5 Calls Sweep (17) near the Ask: 200 @ $4.201 vs 3023 OI; Earnings 11/5 Before Open [est] Ref=$8.585   Benzinga
06:44AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT).   RTTNews
05:06AM EDT  Technical Advisory Group of WHO to Meet on October 26th to Consider Emergency Use Listing for for Ocugen Partner Bharat Biotech's Covaxin   Benzinga
Oct 16, 2021
09:42AM EDT  Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
Oct 15, 2021
04:10PM EDT  CORRECTION: Trader-Circulated gatesfoundation.org Website Was Old Information, Was From Nov. 2019   Benzinga
04:03PM EDT  Ocugen Shares Quiet; Traders Circulate Bill & Melinda Gates Foundation Release Highlighting $19M Grant For Bharat Biotech. BZ NOT: Ocugen Is A Partner Of Bharat Biotech   Benzinga
11:25AM EDT  Ocugen Option Alert: Fri $9 Calls Sweep (3) near the Ask: 677 @ $0.7 vs 8634 OI; Earnings 11/5 Before Open [est] Ref=$9.695   Benzinga
10:42AM EDT  Watching Ocugen Shares; Traders Circulate Research Article Titled 'Prime-Boost Vaccination With Covaxin/BBV152 Induces Heightened Systemic Cytokine and Chemokine Responses'   Benzinga
09:57AM EDT  Ocugen Option Alert: Jan 21 $7.5 Calls at the Ask: 117 @ $3.65 vs 9281 OI; Earnings 11/5 Before Open [est] Ref=$9.5182   Benzinga
Oct 14, 2021
11:13AM EDT  Ocugen Option Alert: Oct 22 $9 Calls Sweep (10) near the Ask: 300 @ $1.561 vs 6989 OI; Earnings 11/5 Before Open [est] Ref=$9.6964   Benzinga
07:19AM EDT  'India's Drug Regulator is seeking more clarity on emergency use of #Covaxin for children above the age of two . Sources tells us, regulator will hold detailed discussions with the Government and Bharat Biotech before waving the green flag.' -CNBC-TV18   Benzinga
Oct 12, 2021
12:58PM EDT  Ocugen Option Alert: Jan 21 $7.5 Calls Sweep (20) near the Ask: 200 @ $3.5 vs 9496 OI; Earnings 11/5 Before Open [est] Ref=$8.94   Benzinga
10:46AM EDT  Ocugen Option Alert: Fri $9 Calls Sweep (29) near the Ask: 387 @ $0.801 vs 8026 OI; Earnings 11/5 Before Open [est] Ref=$9.06   Benzinga
09:40AM EDT  Why Ocugen's Stock Is Trading Higher Today   Benzinga
09:00AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Oct. 12, 2021: RRD, XPO, NTRB, OCGN, ZNGA   Benzinga
05:47AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 5.30 A.M. EDT).   RTTNews
05:38AM EDT  Ocugen Partner Bharat Biotech Says Trial Data in 2-18 Years Age Group for Covaxin Has Been Thoroughly Reviewed by India's Central Drugs Standard Control Organisation and Have Provided Positive Recommendations; Says Now Await Further Regulatory Approvals from CDSCO Prior to Product Launch and Market Availability of Covaxin for Children   Benzinga
05:29AM EDT  Ocugen Shares Rise 20% Premarket After India Regulator Approves Partner Bharat Biotech's Covid Vaccine Covaxin for Children Aged 2-18   Benzinga
04:54AM EDT  India's Subject Expert Committee on Covid-19 Has Granted Emergency Use Approval to Ocugen Partner Bharat Biotech's Covaxin for Children Aged 2-18   Benzinga
04:48AM EDT  India Today Reports Government Expert Panel Approves Covaxin for Kids Aged 2-18   Benzinga
Oct 11, 2021
12:39PM EDT  Ocugen Option Alert: Fri $8 Calls Sweep (18) near the Ask: 1059 @ $0.401 vs 5341 OI; Earnings 11/5 Before Open [est] Ref=$7.61   Benzinga
09:19AM EDT  WHO Vaccine Advisory Body Chair Says It Has Made Policy Recommendations On Use Of Bharat Biotech COVID-19, But Awaits WHO Decision On Regulatory Issues In Next Days   Benzinga
Oct 8, 2021
10:50PM EDT  OCUGEN INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN   Business Wire
Oct 6, 2021
12:12PM EDT  White House Advisor Dr. Fauci Says Merck's COVID-19 Pill Does Not Remove The Need For A Vaccine   Benzinga
08:53AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Oct. 6, 2021: PLTR, SQ, OCGN, LMFA, BTBT   Benzinga
Oct 5, 2021
04:07PM EDT  WHO To Finalize Nod To Ocugen-Partnered Covaxin Next Week: Sources   Benzinga
11:09AM EDT  'WHO Nod For [Bharat/Ocugen's] Covaxin Likely Next Week, Health Body Currently 'Reviewing Data'' -Recent Headline From Indian TV Network News 18   Benzinga
09:23AM EDT  Why Ocugen Shares Are Trading Higher Today   Benzinga
07:24AM EDT  'The representatives of Bharat Biotech are slated to meet WHO experts in a virtual meet at 4:45 pm. During the hour-long meeting, the vaccine manufacturer will present the clinical trial data of #Covaxin through all the three phases' - Mirror Now   Benzinga
Oct 4, 2021
04:22PM EDT  Ocugen 8-K Shows Co. Entered First Amendment To Deal With CanSino Biologics Related To Co.'s OCU410: Will Be Added To Co.'s Existing Collab With CanSino   Benzinga
04:21PM EDT  UPDATE: Ocugen Says Bharat Will Supply Co. With Clinical Trial Materials, Commercial Supplies Of Finished Drug Product Prior To Co.'s Technology Transfer To Third-Party Manufacturer   Benzinga
04:20PM EDT  Ocugen 8-K Shows Co. Entered Development, Commercial Supply Deal With Bharat Biotech For Exclusive Manufacture, Supply Of COVAXIN Clinical Trail Materials, Manufacture, Supply Of COVAXIN Drug Product Components   Benzinga
Oct 3, 2021
09:47AM EDT  India Today Reported on Saturday, Ocugen Partner Bharat Biotech Submitted Data to DCGI for Covaxin for Children Age 2 to 18   Benzinga
Sep 28, 2021
05:27AM EDT  Ocugen Partner Bharat Biotech Tweets Regarding Potential Approval of Covid Vaccine by WHO: 'We do not find it appropriate to speculate or comment on the regulatory approval process & its timeliness'   Benzinga
Sep 27, 2021
06:08PM EDT  Ocugen Spokesperson, When Asked About WHO Delay For COVID-19 Vaccine Partner, Bharat, Reiterates 'Bharat and COVAXIN are scheduled to be presented to the SAGE on Immunization on October 5'   Benzinga
04:09PM EDT  Ocugen-Partnered Covaxin's WHO Clearance Delayed Further Over Queries: Sources   Benzinga
12:40PM EDT  'WHO's Covaxin Clearance Delayed Further Over Technical Queries: Sources' -NDTV Report   Benzinga
Sep 24, 2021
10:50PM EDT  & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN   PR Newswire
Sep 23, 2021
04:19PM EDT  Ocugen To Participate In Fireside Chat At Cantor Global Healthcare Conference Sept. 28 at 8 a.m. EDT   Benzinga
04:10PM EDT  Ocugen, Inc. To Participate In Fireside Chat At Cantor Virtual Global Healthcare Conference Sept. 28   Benzinga
04:08PM EDT  Ocugen, Inc. to Participate in Fireside Chat at the Cantor Virtual   GlobeNewswire Inc
Sep 21, 2021
09:16AM EDT  Watching Shares Of Partner For Indian Manufacturer Of COVID-19 Vaccine, Ocugen, Following Report Indian Gov't. Will Not Buy COVID-19 Shots From Pfizer/BioNTech, Moderna   Benzinga
08:04AM EDT  Ocugen's India-Based Partner Concludes COVID-19 Vaccine Trials In Children: Report   Benzinga
05:14AM EDT  Bharat Biotech has Completed Phase 2 and 3 Clinical Trials of Covaxin for Use in Children 2 to 18 Years; Chairman Krishna Ella said Covaxin Production would Reach 55M Doses in October vs 35M in September   Benzinga
Sep 17, 2021
04:52PM EDT  Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule   GlobeNewswire Inc
01:00PM EDT  'SAGE Meeting at WHO to take up [Ocugen Partner] Bharat Biotech Covaxin issue on October 5' -Tweet From CNN Political Reporter   Benzinga
06:52AM EDT  Ocugen Partner 'Bharat Biotech awaits feedback from WHO for Covaxin emergency use' -India's Business Standard   Benzinga
Sep 14, 2021
03:59PM EDT  Ocugen Option Alert: Oct 15 $7.5 Calls Sweep (5) near the Ask: 200 @ $1.493 vs 9680 OI; Earnings 11/5 Before Open [est] Ref=$7.505   Benzinga
09:48AM EDT  Ocugen Option Alert: Oct 29 $7.5 Calls at the Ask: 134 @ $1.9 vs 406 OI; Earnings 11/5 Before Open [est] Ref=$7.8873   Benzinga
Sep 13, 2021
01:19PM EDT  Shares of Ocugen, Inc. (OCGN) gained nearly 20% on Monday despite no-stock related news to drive the shares.   RTTNews
10:18AM EDT  WHO Gives Nod To Bharat Biotech's COVID-19 Vaccine; Covaxin Expected This Week. BZ NOTE: Ocugen Is A Partner With Bharat Biotech On COVID-19 Vaccine   Benzinga
Sep 10, 2021
10:50PM EDT  OCUGEN INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Ocugen, Inc. - OCGN   Business Wire
Sep 7, 2021
05:22PM EDT  Ocugen, Inc. to Present at Upcoming Citi and H.C. Wainwright   GlobeNewswire Inc
Sep 3, 2021
07:36AM EDT  'Health Ministry in response to an RTI query, says it has made an advance payment to SII for covishield at 215/dose & Bharat Biotech for covaxin at 226/dose, no order for sputnik yet.' - CNBC-TV18   Benzinga
06:31AM EDT  'Bharat Biotech's intranasal vaccine trials begin in Kanpur, UP' - HinduPost   Benzinga
Sep 2, 2021
08:43AM EDT  Ocugen Shares Quiet; India's MoneyControl Reports 'SII, Bharat Biotech made additional 40-50 million doses of COVID-19 vaccine available in August.' BZ NOTE: Bharat Biotech Is An Ocugen Partner   Benzinga
08:42AM EDT  Ocugen Shares Quiet; India's MoneyControl Reports 'SII, Bharat Biotech made additional 40-50 million doses of COVID-19 vaccine available in August'   Benzinga
08:41AM EDT  Ocugen Shares Quiet; MoneyControl Reports 'SII, Bharat Biotech made additional 40-50 million doses of COVID-19 vaccine available in August'   Benzinga
Aug 27, 2021
12:31PM EDT  US President Biden Says Discussed Booster Shot Timeline With National Institutes Of Health's Dr. Fauci, An Added Shot After 5 Months Is Being Discussed   Benzinga
Aug 20, 2021
04:34PM EDT  Ocugen Inc.Announces Inducement Grants   GlobeNewswire Inc
Aug 17, 2021
01:06PM EDT  Canada Province Of Ontario's Chief Medical Officer Says Province Will Offer Third COVID-19 Vaccine Dose To High-Risk People As Early As This Week   Benzinga
10:25AM EDT  UK Updates Summary Of Product Characteristics, Product Information For Moderna's COVID-19 Vaccine To Say Product Authorized In Individuals Aged 12+ Years   Benzinga
Aug 13, 2021
08:00PM EDT  DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Ocugen, Inc. and Encourages Investors to Contact the Firm   Business Wire
09:09AM EDT  Do mRNA COVID-19 Vaccines Cause Skin Or Kidney Disorders? EMA Investigates Possible Links   Benzinga
Aug 12, 2021
05:06PM EDT  Moderna Reports New Study Showing Its COVID-19 Vaccine Maintains Antibodies Against Variants Of Concern To 6 Months   Benzinga
08:28AM EDT  National Institutes Of Health's Dr. Fauci Says Everyone Will Likely Need COVID-19 Vaccine Booster Shots In The Future   Benzinga
Aug 11, 2021
10:43AM EDT  Ocugen Shares Down 7% Wednesday; Co.'s COVID-19 Vaccine Partner, Bharat Biotech, Received Approval To Produce Covaxin At Gujarat Ankleshwar, India Facility (But This Was Largely Expected); Another Recent Article Questioned 'Covaxin to Get Nod Soon?'   Benzinga
Aug 10, 2021
11:28AM EDT  Ocugen Option Alert: Oct 15 $10 Calls at the Ask: 160 @ $1.94 vs 7258 OI; Ref=$9.1818   Benzinga
Aug 6, 2021
04:13PM EDT  Ocugen Filing Shows Registration For ~169.5K Share Common Stock Offering Issuable Upon Exercise Of Warrants Via Selling Shareholders   Benzinga
07:33AM EDT  Ocugen Q2 EPS $(0.13)   Benzinga
07:32AM EDT  Ocugen Provides Business Update and Second Quarter 2021 Financial   GlobeNewswire Inc
04:22AM EDT  Earnings Scheduled For August 6, 2021   Benzinga
Aug 5, 2021
04:32PM EDT  FDA Is Developing A COVID-19 Vaccine Booster Plan, Could Be Ready 'Within Weeks,' 'By September'   Benzinga
09:05AM EDT  Watching Ocugen Shares Following Recent Tweet From India's Times Now Publication '#COVAXIN #WHO clearance likely to come in after August 15'; Ocugen Is Partner For Bharat's Covaxin   Benzinga
08:21AM EDT  From Moderna's Earlier Q2 Earnings Press Release: 'Moderna COVID-19 Vaccine showed 93% efficacy'   Benzinga
Aug 3, 2021
10:25PM EDT  Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN   PR Newswire
12:08PM EDT  CORRECTION: India's Immunologicals Limited May Start Supply 2M Doses Of Ocugen Partner, Bharat's Covaxin   Benzinga
Aug 2, 2021
10:00AM EDT  OCGN, TEDU & HMPT Class Action Deadlines: Bronstein, Gewirtz &   GlobeNewswire Inc
Jul 30, 2021
08:54AM EDT  Ocugen to Host Conference Call on Friday, August 6 at 8:30 a.m. ET   GlobeNewswire Inc
Jul 28, 2021
07:05PM EDT  Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN   PR Newswire
Jul 27, 2021
01:23PM EDT  Ocugen Spokesperson, Responding To Report Brazilian Agency Temporarily Halted Import Authorization For Co./Bharat's COVAXIN, Tells Benzinga 'We're not responsible for exporting COVAXIN to Brazil our scope is only North America...'   Benzinga
11:13AM EDT  Ocugen Shares Down ~2%; Recent Headline Suggested A Brazilian Agency Has Temporarily Halted Import Authorization To Ocugen's Covaxin Import   Benzinga
11:13AM EDT  Brazil Agency Temporarily Halts Import Authorization To Covaxin Import   Benzinga
Jul 26, 2021
03:02PM EDT  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with   GlobeNewswire Inc
Jul 23, 2021
07:40AM EDT  Times Of India Reports Ocugen Partner Bharat Biotech Commits To Supply 500M Doses Of Covaxin To Centre For Immunisation Programme   Benzinga
Jul 16, 2021
09:48PM EDT  Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc.   PR Newswire
04:59PM EDT  Ocugen Inc.Announces Inducement Grants Under Nasdaq   GlobeNewswire Inc
Jul 15, 2021
06:46PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
08:24AM EDT  Why Ocugen Shares Are Rallying Today   Benzinga
07:35AM EDT  Ocugen Announces Initiation of Rolling Submission to Health Canada for COVAXIN   Benzinga
07:34AM EDT  Ocugen, Inc.Announces Initiation of Rolling Submission   GlobeNewswire Inc
Jul 9, 2021
07:17AM EDT  European Medicines Agency Says Currently Too Early To Confirm If, When A Booster Dose For COVID-19 Vaccines Will Be Needed Because Not Yet Enough Data   Benzinga
07:17AM EDT  UPDATE: European Medicines Agency Says Is Engaging With COVID-19 Vaccine Developers To Discuss Plans For Generating Data To Support Booster Dosing, Will Review Data As They Become Available   Benzinga
Jul 7, 2021
11:38PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jul 6, 2021
01:04PM EDT  Ocugen Option Alert: Fri $7 Calls Sweep (8) above Ask!: 350 @ $0.72 vs 676 OI; Earnings 8/13 Before Open [est] Ref=$7.5694   Benzinga
07:25AM EDT  Ocugen Preps US Filings For COVID-19 Vaccine As New Data Shows Overall Efficacy Of Around 79%   Benzinga
07:22AM EDT  Ocugen On Friday Announced Its COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shared Phase 3 Results; Co. Reported 'Efficacy analysis demonstrates COVAXIN to be 93.4% protective against severe symptomatic COVID-19 and 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant'   Benzinga
07:22AM EDT  Ocugen On Friday Announced Its COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shared Phase 3 Results; Co. Reported 'Efficacy analysis demonstrates COVAXIN to be 93.4% protective against severe symptomatic COVID-19 and 65.2% protection against'   Benzinga
Jul 2, 2021
05:42PM EDT  -- Efficacy analysis demonstrates COVAXIN to be 93.4% protective against severe symptomatic COVID-19 -- Efficacy data demonstrates 65.2% protection against the SARS-CoV-2, B.1.617.2 Delta variant -- Adverse events reported were similar to placebo, with 12.4% of subjects experiencing commonly known side effects and less than 0.5% of subjects feeling serious adverse events   GlobeNewswire Inc
Jun 30, 2021
05:02AM EDT  What's Going On With Ocugen (OCGN) Stock Today?   Benzinga
Jun 29, 2021
10:56AM EDT  'Adjuvant Developed with NIH Funding Enhances Efficacy of India's COVID-19 Vaccine' -NIAID Report. BZ NOTE: Occugen Is A Partner With India's Bharat Biotech, Which Will Be Providing Many Of The Nation's COVID-19 Vaccines   Benzinga
10:55AM EDT  'Adjuvant Developed with NIH Funding Enhances Efficacy of India's COVID-19 Vaccine' -NIAID Report. BZ NOTE: Occugen Is A Partner With Bharat Biotech   Benzinga
Jun 28, 2021
04:56PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jun 22, 2021
09:32AM EDT  Ocugen Shares Quiet; Traders Circulate ANI Article Titled 'Bharat Biotech's Covaxin shows 77.8 pc efficacy in Phase III trials, say sources'   Benzinga
Jun 21, 2021
09:12AM EDT  Ocugen, Inc. Announces Ken Inchausti as Head, Investor Relations &   GlobeNewswire Inc
Jun 20, 2021
02:18PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
Jun 18, 2021
04:12PM EDT  Ocugen Inc.Announces Inducement Grants Under Nasdaq   GlobeNewswire Inc
02:53PM EDT  Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Ocugen, Inc. (Ocugen) (NASDAQ: OCGN) in the United States District Court for the Eastern District of Pennsylvania on behalf of those who purchased or otherwise acquired Ocugen publicly traded securities between February 2, 2021 and June 10, 2021, inclusive (the Class Period).   GlobeNewswire Inc
Jun 16, 2021
07:30AM EDT  Ocugen Inc. Set to Join Russell 3000 Index   Benzinga
03:12AM EDT  Novavax COVID-19 Vaccine Could Become Available In India By September, Says Partner   Benzinga
Jun 15, 2021
11:48AM EDT  Ocugen Stock Jumps After Recruiting Jubilant HollisterStier As Manufacturing Partner For COVID-19 Vaccine Candidate   Benzinga
07:56AM EDT  Biopharmaceutical company Ocugen, Inc. (OCGN) announced Tuesday that it has selected Spokane, Washington-based Jubilant HollisterStier as its manufacturing partner for Covaxin to prepare for potential commercial manufacturing of Covaxin for the US and Canadian markets.   RTTNews
07:41AM EDT  Ocugen Selects Jubilant HollisterStier As Manufacturing Partner For Vaccine Candidate COVAXIN   RTTNews
07:31AM EDT  Ocugen Announces Jubilant HollisterStier As Manufacturing Partner For US Production Of COVID-19 Vaccine Candidate, COVAXIN   Benzinga
07:30AM EDT  Ocugen Secures Manufacturing Partnership for US Production of   GlobeNewswire Inc
Jun 11, 2021
11:32AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021   Benzinga
07:48AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
07:02AM EDT  Roth Capital Downgrades Ocugen to Neutral, Lowers Price Target to $6   Benzinga
06:11AM EDT  HC Wainwright & Co. Maintains Buy on Ocugen, Lowers Price Target to $10   Benzinga
Jun 10, 2021
02:30PM EDT  Mid-Afternoon Market Update: Nasdaq Rises 100 Points; Materialise Shares Slide   Benzinga
01:35PM EDT  Ocugen Shares Quiet; Cantor Issues Note 'Ocugen to Pursue a BLA Path for COVAXIN Where We Think Uncertainties Remain; Reiterate Neutral'   Benzinga
12:08PM EDT  Mid-Day Market Update: Yiren Digital Rises Following Q1 Results; Ocugen Shares Slide   Benzinga
11:41AM EDT  UPDATE: Chardan On Ocugen: COVID-19 Vaccine Landscape In U.S. Is Fast-Changing, Moving In Direction That Will Reduce Potential Market Advantages For COVAXIN   Benzinga
11:38AM EDT  Chardan Maintains Neutral On Ocugen, Lowers Price Target From $8 To $4.50   Benzinga
10:28AM EDT  (OCGN) Alert: Did You Lose Money on Your Ocugen Investment? Contact Johnson   PR Newswire
10:17AM EDT  Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Increases to 5%   Benzinga
07:56AM EDT  Ocugen Inc. (OCGN) said that it will no longer pursue an Emergency Use Authorization or EUA for its COVID-19 vaccine candidate COVAXIN. The company noted that it will pursue submission of a biologics license application or BLA for COVAXIN.   RTTNews
07:47AM EDT  Ocugen Names Michael Shine As SVP, Commercial   RTTNews
07:40AM EDT  Ocugen To No Longer Pursue An Emergency Use Authorization For COVAXIN   RTTNews
07:35AM EDT  Ocugen To Pursue Submission Of BLA For Its COVID-19 Vaccine Candidate, COVAXIN   RTTNews
07:35AM EDT  Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.   GlobeNewswire Inc
07:33AM EDT  Ocugen To Pursue A BLA Path In The US For iIt COVID-19 Vaccine Candidate   Benzinga
07:30AM EDT  -- Company intends to work with the FDA towards filing a Biologics License Application (BLA) in the US -- Company to engage with Health Canada to seek authorization under Interim Order for use in Canada   GlobeNewswire Inc
Jun 9, 2021
04:50PM EDT  Ocugen ClinicalTrials.gov Study Record Detail 'COVAXIN in a Pediatric Cohort (COVAXIN-Peds),' Shows Recruiting   Benzinga
Jun 3, 2021
08:01AM EDT  Ocugen Inc. (OCGN) and Bharat Biotech said that they have reached an amendment deal to expand Ocugen's exclusive territory to commercialize COVAXIN to now also include Canada, in addition to Ocugen's existing rights to commercialize COVAXIN in the United States.   RTTNews
07:42AM EDT  Ocugen Expands Exclusive Territory To Commercialize COVAXIN To Include Canada   RTTNews
07:32AM EDT  Ocugen Expands COVAXIN Commercialization Rights to Include Canada   Benzinga
07:30AM EDT  -- Ocugen to have exclusive co-development, manufacturing, and commercialization rights to COVAXIN in Canada, in addition to its existing US rights   GlobeNewswire Inc
May 27, 2021
03:07PM EDT  Microvision, Ocugen Shares On Watch; Hearing Both Companies Being Added To MSCI Small Cap Index Tonight, Alongside Clover Health   Benzinga
09:53AM EDT  Ocugen Late Wednesday Announced Co. Is On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN   Benzinga
08:24AM EDT  The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs   Benzinga
May 26, 2021
10:17PM EDT  Ocugen Inc. (OCGN) confirmed that it plans to submit its Emergency Use Authorization (EUA) application for COVID-19 Vaccine Candidate, COVAXIN, to the U.S. Food & Drug Administration in June.   RTTNews
08:50PM EDT  Ocugen Says On Track To Submit Emergency Use Authorization Application To FDA For COVID-19 Vaccine Candidate, COVAXIN   RTTNews
08:06PM EDT  -- Active discussions with FDA related to COVAXIN initiated late last year -- Master file submitted to FDA on March 26, 2021; awaiting feedback from FDA   GlobeNewswire Inc
12:21PM EDT  FDA May Not Review New COVID-19 Vaccine Emergency Use Requests   Benzinga
May 25, 2021
09:37AM EDT  Bharat Biotech Says Regulatory Approvals For Covaxin In Process In Over 60 Countries Including U.S.   Benzinga
09:35AM EDT  Bharat Biotech Says Regulatory Approvals For Covaxin In Process In Over 60 Countries Including U.S.; Says Application For Emergency Use Listing Summited To WHO; Says Regulatory Approval Expected By July-Sept.   Benzinga
09:26AM EDT  Ocugen Partner For COVID-19 Vaccine, Bharat Biotech, Tweets Image Showing Application For COVID-19 Vaccine Emergency Use Listing Submitted To WHO, Sees Regulatory Approval By Jul.-Sept. 2021   Benzinga
08:10AM EDT  Bharat Biotech's US Partner Ocugen Submits Covaxin Master File for FDA Review   Benzinga
May 24, 2021
11:07AM EDT  Ocugen Option Alert: Jun 18 $10 Calls Sweep (14) near the Ask: 300 @ $0.86 vs 6252 OI; Ref=$8.0897   Benzinga
May 21, 2021
04:00PM EDT  Ocugen Option Alert: Jun 18 $12.5 Calls Sweep (17) near the Ask: 1293 @ $0.801 vs 10315 OI; Ref=$8.67   Benzinga
May 20, 2021
11:19AM EDT  Bharat Biotech Says Will Ramp Up Vaccine Capacity To Make 200M Additional Doses Per Year; Says Product Availability At Gujarat Plant To Begin From Q4 2021   Benzinga
May 18, 2021
11:13AM EDT  Ocugen Option Alert: May 28 $10 Calls Sweep (3) near the Ask: 479 @ $0.801 vs 953 OI; Ref=$9.38   Benzinga
May 12, 2021
09:46AM EDT  Ocugen Option Alert: Jun 18 $12.5 Calls Sweep (15) near the Ask: 519 @ $2.121 vs 9323 OI; Ref=$10.375   Benzinga
May 10, 2021
02:42PM EDT  FDA To Hold AdCom Meeting For Expanding Use COVID-19 Vaccine In Children   Benzinga
01:46PM EDT  Ocugen Option Alert: May 21 $12.5 Calls at the Ask: 824 @ $0.75 vs 24227 OI; Ref=$10.0191   Benzinga
May 7, 2021
12:01PM EDT  Cantor Fitzgerald Downgrades Ocugen to Neutral, Lowers Price Target to $11   Benzinga
10:24AM EDT  Ocugen Shares Quiet; Cantor Downgrades To Neutral   Benzinga
10:03AM EDT  Ocugen shares were trading higher after the company reported Q1 EPS results up from last year.   Benzinga
08:23AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, May 7, 2021: JMIA, TLRY, WKHS, LEDS, OCGN   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC